Fig. 5.
A, B IC50 of adapalene and ranolazine against collagen-induced platelet aggregation. C Adapalene and ranolazine ameliorated the collagen-induced platelet aggregation. D Adapalene and ranolazine showed no effect on ADP-induced platelet aggregation. E Adapalene and ranolazine showed no effect on thrombin-induced platelet aggregation. ap < 0.05 compared to collagen/ADP/Thrombin, bp < 0.05 compared to collagen/ADP/Thrombin + 5 μM ADA, cp < 0.05 compared to collagen/ADP/Thrombin + 10 μM ADA, dp < 0.05 compared to collagen/ADP/Thrombin + 20 μM ADA, ep < 0.05 compared to collagen/ADP/Thrombin + 5 μM RAN, fp < 0.05 compared to collagen/ADP/Thrombin + 10 μM RAN, and gp < 0.05 compared to collagen/ADP/Thrombin + 20 μM RAN in their respective groups. All values are represented in the form of mean ± SD (n = 6). (One-way ANOVA followed by Tukey’s multiple comparison post hoc test). F Comparative activity of adapalene, ranolazine, and tirofiban (temporal study) on platelet aggregation. ap < 0.05 compared to collagen + 5 μM ADA, bp < 0.05 compared to collagen + 5 μM RAN, cp < 0.05 compared to fibrinogen + 5 μM Tirofiban, dp < 0.05 compared to collagen + 10 μM ADA, ep < 0.05 compared to collagen + 10 μM RAN, fp < 0.05 compared to fibrinogen + 10 μM tirofiban, gp < 0.05 compared to collagen + 20 μM ADA, and hp < 0.05 compared to collagen + 20 μM RAN in their respective groups. All values are represented in the form of mean ± SD (n = 6). (One-way ANOVA followed by Tukey’s multiple comparison post hoc test)
